[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported multiple transactions on 09/03/2025 that offset each other, resulting in no net change to total common shares held. On that date the reporting person acquired 203,814 shares through exercises and market purchases and sold 203,814 shares under a Rule 10b5-1 trading plan adopted August 13, 2024. The filings show weighted-average sale prices in three ranges: $58.57–$59.55, $59.60–$60.57, and $60.61–$61.48. Following the transactions the reporting person beneficially owned 180,009 common shares. The Form 4 also lists exercises of non-qualified stock options at strike prices of $32.60, $37.58, and $53.77, with resulting increases in underlying common shares reported in Table II.
Brett P. Monia, Amministratore Delegato e Direttore di Ionis Pharmaceuticals (IONS), ha dichiarato il 03/09/2025 una serie di operazioni che si sono compensate tra loro, senza modificare il numero complessivo di azioni ordinarie possedute. In quella data la persona segnalante ha acquisito 203.814 azioni mediante esercizi e acquisti sul mercato e ha venduto 203.814 azioni nell'ambito di un piano di trading ai sensi della Rule 10b5-1 adottato il 13 agosto 2024. I documenti indicano prezzi medi ponderati di vendita in tre fasce: 58,57–59,55 $, 59,60–60,57 $ e 60,61–61,48 $. Dopo le operazioni la persona segnalante deteneva in modo beneficiario 180.009 azioni ordinarie. Il Modulo 4 riporta inoltre l'esercizio di opzioni non qualificate con prezzi di esercizio di 32,60 $, 37,58 $ e 53,77 $, con conseguenti aumenti delle azioni sottostanti riportati nella Tabella II.
Brett P. Monia, Director Ejecutivo y miembro del consejo de Ionis Pharmaceuticals (IONS), informó el 03/09/2025 sobre múltiples transacciones que se compensaron entre sí, sin producir un cambio neto en el número total de acciones ordinarias en su posesión. Ese día la persona informante adquirió 203.814 acciones mediante ejercicios y compras en el mercado y vendió 203.814 acciones conforme a un plan de negociación Rule 10b5-1 adoptado el 13 de agosto de 2024. Los registros muestran precios de venta promedio ponderados en tres rangos: 58,57–59,55 $, 59,60–60,57 $ y 60,61–61,48 $. Tras las operaciones, la persona informante poseía de forma beneficiaria 180.009 acciones ordinarias. El Formulario 4 también detalla ejercicios de opciones sobre acciones no calificadas con precios de ejercicio de 32,60 $, 37,58 $ y 53,77 $, con los aumentos correspondientes en las acciones subyacentes consignados en la Tabla II.
Ionis Pharmaceuticals(IONS)의 최고경영자 겸 이사인 Brett P. Monia는 2025년 9월 3일 여러 건의 거래를 보고했으며, 이 거래들은 서로 상쇄되어 보유한 보통주 총수에는 순변동이 없었습니다. 해당 일자에 보고자는 옵션 행사 및 시장 매수를 통해 203,814주를 취득했고, 2024년 8월 13일 채택된 Rule 10b5-1 거래계획에 따라 203,814주를 매도했습니다. 제출 서류에는 가중평균 매도 가격이 세 구간으로 표시되어 있습니다: $58.57–$59.55, $59.60–$60.57, 및 $60.61–$61.48. 거래 이후 보고자는 180,009주의 보통주를 실질적으로 보유하고 있었습니다. Form 4에는 또한 행사가격이 $32.60, $37.58, 및 $53.77인 비자격 스톡옵션 행사 내용이 기재되어 있으며, 그에 따른 기초 보통주 수의 증가가 표 II에 보고되어 있습니다.
Brett P. Monia, directeur général et administrateur d'Ionis Pharmaceuticals (IONS), a déclaré le 03/09/2025 plusieurs opérations qui se sont compensées, sans entraîner de variation nette du nombre total d'actions ordinaires détenues. À cette date, la personne débitrice a acquis 203 814 actions par des exercices et des achats sur le marché et a vendu 203 814 actions dans le cadre d'un plan de transaction Rule 10b5-1 adopté le 13 août 2024. Les documents indiquent des prix de vente moyens pondérés dans trois fourchettes : 58,57–59,55 $, 59,60–60,57 $ et 60,61–61,48 $. À l'issue des opérations, la personne déclarante détenait à titre bénéficiaire 180 009 actions ordinaires. Le formulaire 4 mentionne également des exercices d'options non qualifiées avec des prix d'exercice de 32,60 $, 37,58 $ et 53,77 $, entraînant des augmentations des actions sous-jacentes consignées dans le tableau II.
Brett P. Monia, Chief Executive Officer und Direktor von Ionis Pharmaceuticals (IONS), meldete am 03.09.2025 mehrere Transaktionen, die sich gegenseitig aufhoben und zu keiner Nettoveränderung der insgesamt gehaltenen Stammaktien führten. An diesem Tag erwarb die meldepflichtige Person 203.814 Aktien durch Ausübungen und Käufe am Markt und verkaufte 203.814 Aktien im Rahmen eines Rule‑10b5‑1‑Tradingplans, der am 13. August 2024 eingeführt wurde. Die Unterlagen führen gewichtete Durchschnittsverkaufspreise in drei Bereichen auf: $58,57–$59,55, $59,60–$60,57 und $60,61–$61,48. Nach den Transaktionen hielt die meldepflichtige Person wirtschaftlich 180.009 Stammaktien. In Formular 4 sind zudem die Ausübungen nicht qualifizierter Aktienoptionen zu Ausübungspreisen von $32,60, $37,58 und $53,77 aufgeführt, mit den daraus resultierenden Erhöhungen der zugrundeliegenden Stammaktien in Tabelle II.
- Acquisitions and option exercises totaling 203,814 shares increased immediate liquidity from exercised options
- Sales executed under a Rule 10b5-1 trading plan, indicating pre-planned compliance with insider trading rules
- Detailed footnotes disclose weighted-average price ranges and offer to provide per-price breakdowns on request
- Substantial gross sales of 203,814 shares on a single date, which may be viewed as significant insider liquidity
- Beneficial ownership decreased to 180,009 shares after the transactions, reflecting a lower reported holding
Insights
Insider executed option exercises and matched sales under a 10b5-1 plan; net share position unchanged.
The Form 4 shows coordinated option exercises and open-market sales totaling 203,814 shares on 09/03/2025. Sales were executed under a pre-established Rule 10b5-1 plan, with weighted-average prices spanning about $58.57 to $61.48. Exercises occurred at strike prices between $32.60 and $53.77, converting options into common shares. The activity appears liquidity-driven rather than a directional change in ownership: the total acquired equals total sold and the post-transaction beneficial ownership is reported as 180,009 shares.
Transactions comply with a 10b5-1 plan and reflect routine insider liquidity and option exercises.
The disclosure specifically notes a Rule 10b5-1 trading plan adopted August 13, 2024, and provides weighted-average sale price ranges with an undertaking to disclose per-price details on request. Multiple option exercises are disclosed with grant/exercise dates and expiration dates, and Table II reconciles options converted into common shares. Documentation and footnotes are consistent with transparent insider reporting practices, with no unexplained transfers or indirect holdings reported.
Brett P. Monia, Amministratore Delegato e Direttore di Ionis Pharmaceuticals (IONS), ha dichiarato il 03/09/2025 una serie di operazioni che si sono compensate tra loro, senza modificare il numero complessivo di azioni ordinarie possedute. In quella data la persona segnalante ha acquisito 203.814 azioni mediante esercizi e acquisti sul mercato e ha venduto 203.814 azioni nell'ambito di un piano di trading ai sensi della Rule 10b5-1 adottato il 13 agosto 2024. I documenti indicano prezzi medi ponderati di vendita in tre fasce: 58,57–59,55 $, 59,60–60,57 $ e 60,61–61,48 $. Dopo le operazioni la persona segnalante deteneva in modo beneficiario 180.009 azioni ordinarie. Il Modulo 4 riporta inoltre l'esercizio di opzioni non qualificate con prezzi di esercizio di 32,60 $, 37,58 $ e 53,77 $, con conseguenti aumenti delle azioni sottostanti riportati nella Tabella II.
Brett P. Monia, Director Ejecutivo y miembro del consejo de Ionis Pharmaceuticals (IONS), informó el 03/09/2025 sobre múltiples transacciones que se compensaron entre sí, sin producir un cambio neto en el número total de acciones ordinarias en su posesión. Ese día la persona informante adquirió 203.814 acciones mediante ejercicios y compras en el mercado y vendió 203.814 acciones conforme a un plan de negociación Rule 10b5-1 adoptado el 13 de agosto de 2024. Los registros muestran precios de venta promedio ponderados en tres rangos: 58,57–59,55 $, 59,60–60,57 $ y 60,61–61,48 $. Tras las operaciones, la persona informante poseía de forma beneficiaria 180.009 acciones ordinarias. El Formulario 4 también detalla ejercicios de opciones sobre acciones no calificadas con precios de ejercicio de 32,60 $, 37,58 $ y 53,77 $, con los aumentos correspondientes en las acciones subyacentes consignados en la Tabla II.
Ionis Pharmaceuticals(IONS)의 최고경영자 겸 이사인 Brett P. Monia는 2025년 9월 3일 여러 건의 거래를 보고했으며, 이 거래들은 서로 상쇄되어 보유한 보통주 총수에는 순변동이 없었습니다. 해당 일자에 보고자는 옵션 행사 및 시장 매수를 통해 203,814주를 취득했고, 2024년 8월 13일 채택된 Rule 10b5-1 거래계획에 따라 203,814주를 매도했습니다. 제출 서류에는 가중평균 매도 가격이 세 구간으로 표시되어 있습니다: $58.57–$59.55, $59.60–$60.57, 및 $60.61–$61.48. 거래 이후 보고자는 180,009주의 보통주를 실질적으로 보유하고 있었습니다. Form 4에는 또한 행사가격이 $32.60, $37.58, 및 $53.77인 비자격 스톡옵션 행사 내용이 기재되어 있으며, 그에 따른 기초 보통주 수의 증가가 표 II에 보고되어 있습니다.
Brett P. Monia, directeur général et administrateur d'Ionis Pharmaceuticals (IONS), a déclaré le 03/09/2025 plusieurs opérations qui se sont compensées, sans entraîner de variation nette du nombre total d'actions ordinaires détenues. À cette date, la personne débitrice a acquis 203 814 actions par des exercices et des achats sur le marché et a vendu 203 814 actions dans le cadre d'un plan de transaction Rule 10b5-1 adopté le 13 août 2024. Les documents indiquent des prix de vente moyens pondérés dans trois fourchettes : 58,57–59,55 $, 59,60–60,57 $ et 60,61–61,48 $. À l'issue des opérations, la personne déclarante détenait à titre bénéficiaire 180 009 actions ordinaires. Le formulaire 4 mentionne également des exercices d'options non qualifiées avec des prix d'exercice de 32,60 $, 37,58 $ et 53,77 $, entraînant des augmentations des actions sous-jacentes consignées dans le tableau II.
Brett P. Monia, Chief Executive Officer und Direktor von Ionis Pharmaceuticals (IONS), meldete am 03.09.2025 mehrere Transaktionen, die sich gegenseitig aufhoben und zu keiner Nettoveränderung der insgesamt gehaltenen Stammaktien führten. An diesem Tag erwarb die meldepflichtige Person 203.814 Aktien durch Ausübungen und Käufe am Markt und verkaufte 203.814 Aktien im Rahmen eines Rule‑10b5‑1‑Tradingplans, der am 13. August 2024 eingeführt wurde. Die Unterlagen führen gewichtete Durchschnittsverkaufspreise in drei Bereichen auf: $58,57–$59,55, $59,60–$60,57 und $60,61–$61,48. Nach den Transaktionen hielt die meldepflichtige Person wirtschaftlich 180.009 Stammaktien. In Formular 4 sind zudem die Ausübungen nicht qualifizierter Aktienoptionen zu Ausübungspreisen von $32,60, $37,58 und $53,77 aufgeführt, mit den daraus resultierenden Erhöhungen der zugrundeliegenden Stammaktien in Tabelle II.
FAQ
What insider transactions did Ionis (IONS) CEO Brett Monia report on 09/03/2025?
Were the sales by Brett Monia executed under a 10b5-1 plan?
What price ranges were reported for the sales on the Form 4?
What option exercises are disclosed in the filing?
Does the Form 4 indicate any indirect beneficial ownership?
